Clinical Trial Details

A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

IRB Protocol Number
S1900K

Clinical Trial Categories

  • Lung Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: Men or women, ages 18 or older, diagnosed with MET Exon 14 skipping mutation-positive Stage IV non-small cell lung cancer (NSCLC)

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.